Biosimilar Litigation: Amgen Sues Samsung Bioepis To Enforce 180-Day Notice Requirement
Executive Summary
Although Samsung has not provided 180-day advance notice of commercialization for Eticovo, its recently approved biosimilar to Enbrel, Amgen seeks a preliminary injunction because it has reason to believe the company is prepared to launch ‘imminently.’
You may also be interested in...
Amgen Could Block Enbrel Biosimilars For Another Decade As Court Rules Stealth Patents Valid
Court rejects Sandoz's arguments that patents covering Enbrel's active ingredient and method of manufacture are invalid; decision comes three years after FDA approved Sandoz's biosimilar.
Keeping Track: A Glut Of Big Approvals While Lartruvo Makes Its Market Exit
The latest drug development news and highlights from our US FDA Performance Tracker.